According to recent analysis from the Tufts Center for the Study of Drug Development (Tufts CSDD), drug companies that develop and launch new products faster than their peers earn higher revenues and have lower development costs. Between 2000 and 2005, the fastest companies gained an average of $1.1 billion in incremental prescription revenue and saved an average of $30 million in development costs, as compared with the slowest companies, Tufts CSDD reported. “Speed demon companies—the faste...